Valuation Update With 7 Day Price Move • 5h
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩6,440, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total returns to shareholders of 33% over the past three years. Buy Or Sell Opportunity • Jun 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩5,680. The fair value is estimated to be ₩7,147, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 81%. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩5,920, the stock trades at a trailing P/E ratio of 5.4x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 13% over the past three years. お知らせ • Jun 11
Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 1,000 million worth of its shares. Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 1,000 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is Enhancement of Shareholder Value. The repurchase program will expire on June 10, 2027. As of June 9, 2026, the company had 1,036,721 shares within scope available for dividend and had no shares in treasury through other repurchase. Buy Or Sell Opportunity • Jun 01
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩5,450. The fair value is estimated to be ₩7,091, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 81%. Valuation Update With 7 Day Price Move • May 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩6,280, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years. お知らせ • Apr 15
Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares. Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase. Buy Or Sell Opportunity • Mar 12
Now 23% overvalued Over the last 90 days, the stock has fallen 18% to ₩7,330. The fair value is estimated to be ₩5,970, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to grow by 33% in the next year. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩6,350, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past year. お知らせ • Mar 04
Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026 Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩7,610, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 110% over the past year. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩9,230, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 202% over the past year. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩8,450, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past year. お知らせ • Sep 19
Cell Bio Human Tech Co.,Ltd announced that it expects to receive KRW 3.5 billion in funding from Mirae Asset Securities Co., Ltd. Cell Bio Human Tech Co.,Ltd announced a private placement to issue Zero Coupon Series 1 Unsecured Private Equity Convertible Bonds due September 26, 2032 for gross proceeds of KRW 3,500,000,000 on September 18, 2025. The transaction will include participation from new investor Mirae Asset Securities Co., Ltd. (as the trustee of this fund). The transaction has been approved by shareholders, expected to close on September 26, 2025, 100% convertible into 341,930 shares at a fixed conversion price of KRW 10,236 from October 26, 2025 to August 26, 2032, bears zero coupon rate, zero maturity rate and matures on September 26, 2032. New Risk • Aug 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₩86.5b market cap, or US$62.2m). New Risk • Aug 28
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩74.1b market cap, or US$53.4m). Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩8,080, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 148% over the past year. New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩62.1b market cap, or US$45.9m). Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩7,510, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 86% over the past year. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩5,330, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 32% over the past year. お知らせ • Feb 27
Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025 Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea お知らせ • Feb 20
Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares. Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩3,055, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past year. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩3,580, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past year. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩27.2b market cap, or US$19.9m). New Risk • Jun 08
New major risk - Revenue and earnings growth Earnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩36.5b market cap, or US$26.4m). お知らせ • Mar 27
Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares. Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.